923 results on '"Ratjen F"'
Search Results
2. P063 ELX/TEZ/IVA has beneficial effects on clinical outcomes and quality of life in people with cystic fibrosis in the real-world TRAJECTORY study
3. P236 Investigating the impact of elexacaftor/tezacaftor/ivacaftor therapy on longitudinal oropharyngeal microbiome dynamics in children with cystic fibrosis
4. Building global development strategies for cf therapeutics during a transitional cftr modulator era
5. 137 Long-term safety and efficacy of elexacaftor-tezacaftor-ivacaftor in children aged 2 and older with cystic fibrosis and at least one F508del allele: 48-week results of an open-label extension study
6. 129 Response in imaging and lung function outcomes in the HyPOINT study
7. 709 Randomized, double-blind, placebo-controlled trial of oral prednisone as adjunctive treatment in pulmonary exacerbations in cystic fibrosis (PIPE Study)
8. 124 Is home spirometry accurate? Comparison between home and office spirometry in the PROMISE study
9. 540 Impact of elexacaftor-tezacaftor-ivacaftor on gastrointestinal outcomes, inflammation, exocrine pancreatic function, and fat malabsorption: Report of PROMISE PEDS GI
10. 141 Factors associated with significantly corrected sweat chloride in people with cystic fibrosis taking elexacaftor-tezacaftor-ivacaftor—results from the PROMISE and RECOVER studies
11. 133 Long-term safety and efficacy of elexacaftor-tezacaftor-ivacaftor in children aged 6 and older with cystic fibrosis and at least one F508del allele: 144-week results of an open-label extension study
12. 711 Patterns of early Staphylococcus aureus infection and lung function in children with cystic fibrosis
13. 712 Correlations between in-vitro and clinical drug response to CFTR modulators
14. 112 The lung clearance index to inform clinical decision-making in early cystic fibrosis lung disease: findings from a prospective study
15. WS01.01 Cardiopulmonary exercise testing provides prognostic information in advanced cystic fibrosis lung disease
16. P077 Clinical and functional efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis carrying the N1303K mutation
17. EPS5.02 Faecal microbiota changes in patients with cystic fibrosis with 6 months of elexacaftor/tezacaftor/ivacaftor: preliminary findings from the PROMISE study
18. Treatment Response to Pulmonary Exacerbation in Primary Ciliary Dyskinesia
19. 165 Hyperpolarized xenon gas ventilation magnetic resonance imaging detects lung ventilation improvement in children with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor in a multisite study
20. 213 Composition of fecal microbiota and bile acid abundances with 1 month of elexacaftor/tezacaftor/ivacaftor in pediatric patients with cystic fibrosis: Preliminary findings from PROMISE Pediatrics Study
21. 176 How frequently should the lung clearance index be measured in children with cystic fibrosis?
22. 161 Elexacaftor/tezacaftor/ivacaftor reduces trapped gas in children with cystic fibrosis
23. 429 Myeloperoxidase in extracellular vesicles isolated from airways of children with cystic fibrosis
24. 535 Detection of Staphylococcus aureus in exhaled breath of children with cystic fibrosis
25. 224 Elexacaftor/tezacaftor/ivacaftor alters gastrointestinal symptoms and inflammation: Report of PROMISE Pediatric Gastrointestinal Study
26. 160 Monitoring Response to elexacaftor/tezacaftor/ivacaftor treatment in pediatric cystic fibrosis lung disease using free-breathing magnetic resonance imaging
27. 122 Changes in lung clearance index in newborns who screened positive for cystic fibrosis with an inconclusive diagnosis
28. 163 Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in children 6 years and older with cystic fibrosis and at least one F508del alleles: 96-week interim results from an open-label extension study
29. 492 Effect of antibiotic changes during treatment of cystic fibrosis pulmonary exacerbations
30. 177 Elexacaftor/tezacaftor/ivacaftor treatment in pediatric cystic fibrosis lung disease reduces ventilation heterogeneity measured using hyperpolarized 129xenon multiple-breath washout magnetic resonance imaging
31. 173 Effectiveness of elexacaftor/tezacaftor/ivacaftor in children with cystic fibrosis: The pediatric PROMISE study
32. Breath profiles in cystic fibrosis children treated with CFTR modulators
33. Volume of trapped gas in adolescents with cystic fibrosis starting CFTR modulator thera
34. Efficacy of antibiotic eradication therapy of early Pseudomonas aeruginosa infection in children with primary ciliary dyskinesia
35. Estimating the minimum sample size for interventional research using the lung clearance index
36. Automated airway-artery analysis on chest CT confirms positive effect of inhaled hypertonic saline in preschool children with cystic fibrosis
37. Feasibility of Hyperpolarized 129Xe MRI in Primary Ciliary Dyskinesia
38. Comparison of sensor crosstalk-corrected N2 versus SF6 multiple breath washout outcomes
39. Impact of Pseudomonas aeruginosa antibiotic eradication therapy on lung function decline in cystic fibrosis
40. Respiratory symptom scores to capture acute respiratory events in children with cystic fibrosis
41. Extrazelluläre Vesikel im Sputum von Kindern mit zystischer Fibrose und pulmonaler Exazerbation
42. Profil leicht verdampfender organischer Substanzen in der Ausatemluft von Kindern mit Mukoviszidose
43. Patterns of allergic sensitization and atopic dermatitis from 1 to 3 years: Effects on allergic diseases
44. Feasibility of ultrashort echo time (ute) mri to evaluate the effect of lumacaftor/ivacaftor therapy in children with cystic fibrosis (cf) homozygous for f508del: P254
45. Effect of lumacaftor/ivacaftor on total, bronchiectasis, and air trapping computed tomography (ct) scores in children homozygous for f508del-cftr: exploratory imaging substudy: S93
46. WS18.06 Fully automated analysis of airway-artery dimensions on chest-computed tomography in preschool children with cystic fibrosis to evaluate the effect of inhaled hypertonic saline
47. Diagnostik
48. A randomized controlled trial of inhaled l-Arginine in patients with cystic fibrosis
49. Atemwegserkrankung
50. Diagnostik der cystischen Fibrose
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.